An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO inhibitor) vs placebo in the treatment of moderate to severe COPD.

Trial Identifier: D6582C00001
Sponsor: AstraZeneca
NCTID:: NCT05492877
Start Date: November 2022
Primary Completion Date: August 2024
Study Completion Date: August 2024
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations